AccuStem Q3: $15,303 Cash Left, Going Concern Reaffirmed, $1.5M IPR&D Charge
ACUT is trading near its 52-week low of $0.117 (0.9% above the low).
Summary
AccuStem's Q3 10-Q shows only $15,303 of cash, a $5.98M working capital deficit, and a reaffirmed going concern warning, with the $1.87M quarterly loss driven by a $1.5M non-cash IPR&D write-off. The company is surviving on related-party funding and says it is pursuing new equity financing.
Key Events · Earnings and Guidance · ACUT
-
Going Concern Warning Reaffirmed
Management states the company does not have sufficient cash and current assets to support operations for at least 12 months from the issuance date of these financial statements.
-
Cash Down to $15,303
Cash was $15,303 at September 30, 2026 against total current liabilities of $6,063,330, leaving a working capital deficit of $5,980,129.
-
$1.5M Non-Cash IPR&D Charge
The Gensignia IP Limited acquisition closed in the quarter and the acquired in-process R&D was expensed under ASC 730, driving the $1,869,895 Q3 net loss versus $399,897 a year earlier.
-
Survival Rests on Related-Party Funding
Related party payable to Tiziana reached $5,363,673, including $4,286,500 of funding support and $935,000 of advances during the nine months; Tiziana owns about 10.91% of the company.
Analysis · ACUT · Life Sciences
AccuStem ended September with just $15,303 of cash against $6.06M of current liabilities, and management explicitly says it cannot fund operations for the next 12 months without new money. The quarter's $1.87M loss is mostly a non-cash $1.5M write-off of the Gensignia IPR&D, but the cash position is the real story: the company is being kept alive by Tiziana, which has now advanced $4.29M in funding support and is owed $5.36M in total. Management says it is in discussions for a private investment and public equity raise — any deal done at today's $0.118 price would be deeply dilutive to the 16.07M shares outstanding. The material weakness in financial reporting controls remains unremediated.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACUT was trading at $0.12 on OTC in the Life Sciences sector, with a market capitalization of approximately $1.9M. The 52-week trading range was $0.12 to $2.33. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.